|
gptkbp:instance_of
|
gptkb:venture_capital
|
|
gptkbp:assets
|
over €1 billion
|
|
gptkbp:focus
|
life sciences
|
|
gptkbp:founded
|
gptkb:1972
|
|
gptkbp:founder
|
gptkb:Antoine_Papiernik
|
|
gptkbp:headquarters
|
gptkb:Paris,_France
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sofinnova Partners
|
|
gptkbp:investment
|
long-term value creation
growth stage
early stage
|
|
gptkbp:investment_focus
|
gptkb:biotechnology
gptkb:pharmaceuticals
gptkb:health_services
gptkb:medical_devices
therapeutics
digital health
diagnostics
|
|
gptkbp:investment_strategy
|
sector-focused
|
|
gptkbp:notable_investments
|
gptkb:Celyad
gptkb:Actelion
Therachon
Erytech Pharma
Gen Sight Biologics
|
|
gptkbp:number_of_employees
|
approximately 30
|
|
gptkbp:partnership
|
gptkb:Bpifrance
gptkb:European_Investment_Fund
Sofinnova Capital
|
|
gptkbp:portfolio_company
|
gptkb:Vaxart
gptkb:Medi_Beacon
gptkb:Medi_Wound
gptkb:Sutro_Biopharma
gptkb:Aprea_Therapeutics
gptkb:Cure_Vac
gptkb:Aptinyx
Sientra
|
|
gptkbp:region
|
gptkb:Europe
gptkb:North_America
|
|
gptkbp:website
|
www.sofinnova.com
|
|
gptkbp:bfsParent
|
gptkb:Tessera_Therapeutics
gptkb:Spark_Therapeutics
gptkb:Caresyntax
gptkb:Decibel_Therapeutics
|
|
gptkbp:bfsLayer
|
5
|